by Elizabeth Krutoholow Newly approved therapeutics for chronic myelogenous leukemia (CML) or so-called second generation tyrosine kinase inhibitors (TKIs) like Ariad’s Iclusig and Pfizer’s Bosulif will require data showing survival improvements before clinicians adopt them in the front-line setting, according to Dr. Elias Jabbour, Associate Professor in the Department of Leukemia, at The University of Texas MD Anderson Cancer Center. Read more >>>
Take a risk free 30 day trial to Bloomberg’s Bankruptcy newsletter - click here.
Press play to start the video. After the introduction, the book review will automatically open at the end. Take a free 30 day trial to our Municipal Market newsletter here.
By Andrew Berens, MD Senior Healthcare Analyst, Bloomberg Industries Sanofi’s multiple sclerosis (MS) drug Lemtrada may soon be recommended for European approval, where revenue is especially important to holders of Genzyme contingent value rights linked to the drug’s success. Read more >>>
Click here to view full sample. The Bloomberg Brief newsletters are subscription products. To take a trial to our market leading Economics newsletter click here or use the navigation on the right to select the appropriate title.
Banks sold $548.3 million of U.S. structured notes in May that offer protection from rising interest rates, the most in almost two years, on concerns that borrowing costs may rise as the Federal Reserve prepares to reduce unprecedented stimulus measures. The most popular such securities were those that eventually yield a coupon that floats above the London interbank [...]
Losses on junk-bond ETFs are outpacing the broader U.S. high-yield market by the most in three years, signaling a deepening slump for debt that traded at record-high prices less than a month ago. Click Here for More
To take a free 30 day trial to our market leading bankruptcy newsletter click here
Compiled by Sam Fazeli, Director Bloomberg Industries Europe and Asthika Goonewardene, Pharmaceuticals Equity Research Analyst AstraZeneca’s bid to buy Omthera is driven by Epanova, an experimental treatment for patients with high levels of triglycerides that could be combined with the large pharma company’s best-selling medicine Crestor in an effort to stave off generic competition. [...]